- Home
- STXS vs INZY Comparison
STXS vs INZY Comparison
Compare STXS & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- INZY
- Stock Information
- Founded
- STXS 1990
- INZY 2015
- Country
- STXS United States
- INZY United States
- Employees
- STXS N/A
- INZY N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- STXS Health Care
- INZY Health Care
- Exchange
- STXS Nasdaq
- INZY Nasdaq
- Market Cap
- STXS N/A
- INZY 188.2M
- IPO Year
- STXS 2004
- INZY 2020
- Fundamental
- Price
- STXS $2.49
- INZY $1.36
- Analyst Decision
- STXS Strong Buy
- INZY Strong Buy
- Analyst Count
- STXS 2
- INZY 8
- Target Price
- STXS $4.50
- INZY $17.75
- AVG Volume (30 Days)
- STXS 412.8K
- INZY 1.0M
- Earning Date
- STXS 03-03-2025
- INZY 03-11-2025
- Dividend Yield
- STXS N/A
- INZY N/A
- EPS Growth
- STXS N/A
- INZY N/A
- EPS
- STXS N/A
- INZY N/A
- Revenue
- STXS $25,143,000.00
- INZY N/A
- Revenue This Year
- STXS $3.73
- INZY N/A
- Revenue Next Year
- STXS $54.27
- INZY N/A
- P/E Ratio
- STXS N/A
- INZY N/A
- Revenue Growth
- STXS N/A
- INZY N/A
- 52 Week Low
- STXS $1.66
- INZY $1.24
- 52 Week High
- STXS $3.29
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- STXS 61.67
- INZY 29.28
- Support Level
- STXS $2.26
- INZY $1.35
- Resistance Level
- STXS $2.52
- INZY $1.62
- Average True Range (ATR)
- STXS 0.13
- INZY 0.13
- MACD
- STXS 0.03
- INZY 0.04
- Stochastic Oscillator
- STXS 89.80
- INZY 32.89
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.